Extended Data Fig. 3: HSCs^LT of tumor-bearing mice are myeloid-primed.

a, Frequency and cell number of total CD11b⁺ cells obtained after in vitro HSC^LT myeloid differentiation from WT and PyMT mice (see Fig. 2a). Dots represent individual replicate wells (n = 9 mice, pool of 4 experiments). b, Total cell number obtained after in vitro HSC^LT myeloid differentiation from tumor-free or Py230 tumor-bearing mice (n = 3, technical triplicates for each individual mouse, pool of 2 experiments). c, Frequency and cell numbers of Ly6G⁺CD11b^int cells obtained after in vitro HSC^LT myeloid differentiation from tumor-free or Py230 tumor-bearing mice (n = 3, triplicates for each individual mouse, pool of 2 experiments). d, e, Frequency of CD45.2⁺ donor-derived cells among TCRß⁺ T cells after the #1 transplant (d)(n = 17 WT and 12 PyMT mice at 2 and 4 weeks, n = 9 WT and 7 PyMT mice at 8 and 12 weeks, n = 16 WT and 12 PyMT mice at 16 weeks, pool of 2 experiments) and after the #2 transplant (e)(n = 14 WT and 11 PyMT mice at 2 weeks, n = 14 WT and 12 PyMT mice at 4, 8, 12 and 16 weeks, pool of 2 experiments) of HSCs^LT from WT or PyMT mice in irradiated CD45.1⁺ recipients. Data are the mean ± s.d. P value < 0.05 are depicted and were obtained using two-tailed t-test (a, b, and c) corrected for multiple comparison using Holm-Šídák method (d and e).

Source data